Alerts will be sent to your verified email
Verify Email
BAFNAPH
|
Bafna Pharma
|
Medicamen Biotech
|
Medico Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-52.11 % | 6.92 % | 13.93 % |
|
5yr average Equity Multiplier
|
3.77 | 1.44 | 2.07 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 0.55 | 1.49 |
|
5yr Avg Net Profit Margin
|
-36.55 % | 8.69 % | 4.73 % |
|
Price to Book
|
4.8 | 1.92 | 6.42 |
|
P/E
|
49.22 | 43.02 | 38.86 |
|
5yr Avg Cash Conversion Cycle
|
0.18 Days | 49.75 Days | 53.33 Days |
|
Inventory Days
|
87.65 Days | 84.58 Days | 48.95 Days |
|
Days Receivable
|
132.64 Days | 139.4 Days | 129.15 Days |
|
Days Payable
|
210.48 Days | 264.75 Days | 124.28 Days |
|
5yr Average Interest Coverage Ratio
|
-5.68 | 7.03 | 11.55 |
|
5yr Avg ROCE
|
-11.61 % | 10.34 % | 20.03 % |
|
5yr Avg Operating Profit Margin
|
-21.98 % | 15.51 % | 7.11 % |
|
5 yr average Debt to Equity
|
1.41 | 0.15 | 0.26 |
|
5yr CAGR Net Profit
|
12.0 % | -11.57 % | 31.26 % |
|
5yr Average Return on Assets
|
-16.11 % | 4.73 % | 6.88 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 40.46 % | 62.59 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-15.12 % | -3.14 % | -10.75 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Bafna Pharma
|
Medicamen Biotech
|
Medico Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|